Grifols Future Growth

Future criteria checks 3/6

Grifols is forecast to grow earnings and revenue by 28.8% and 5.9% per annum respectively. EPS is expected to grow by 31.5% per annum. Return on equity is forecast to be 11.5% in 3 years.

Key information

28.8%

Earnings growth rate

31.5%

EPS growth rate

Biotechs earnings growth	23.7%
Revenue growth rate	5.9%
Future return on equity	11.5%
Analyst coverage	Good
Last updated	01 May 2024

Recent future growth updates

Recent updates

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Jan 03

Grifols Class B: Buy The Recovery In The U.S. Plasma Business

Nov 11

Grifols S.A. goes ex-dividend tomorrow

Oct 29

Earnings and Revenue Growth Forecasts

NasdaqGS:GRFS - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	8,033	822	873	1,207	7
12/31/2025	7,641	722	687	1,014	13
12/31/2024	7,097	468	530	856	14
12/31/2023	6,592	59	-87	208	N/A
9/30/2023	6,535	23	-217	119	N/A
6/30/2023	6,479	8	-505	-146	N/A
3/31/2023	6,358	47	-485	-107	N/A
12/31/2022	6,064	208	-386	-11	N/A
9/30/2022	5,549	149	-272	50	N/A
6/30/2022	5,207	66	-36	289	N/A
3/31/2022	5,016	112	137	454	N/A
12/31/2021	4,933	189	282	597	N/A
9/30/2021	5,044	361	400	727	N/A
6/30/2021	5,199	667	597	909	N/A
3/31/2021	5,231	562	847	1,183	N/A
12/31/2020	5,340	619	748	1,110	N/A
9/30/2020	5,392	687	663	1,081	N/A
6/30/2020	5,353	557	551	964	N/A
3/31/2020	5,235	697	425	842	N/A
12/31/2019	5,099	625	157	569	N/A
9/30/2019	4,961	552	309	668	N/A
6/30/2019	4,790	565	275	634	N/A
3/31/2019	4,620	568	147	477	N/A
12/31/2018	4,487	597	430	737	N/A
9/30/2018	4,332	699	365	680	N/A
6/30/2018	4,246	704	405	712	N/A
3/31/2018	4,279	672	473	789	N/A
12/31/2017	4,318	663	519	842	N/A
9/30/2017	4,348	571	N/A	751	N/A
6/30/2017	4,291	559	N/A	765	N/A
3/31/2017	4,153	554	N/A	640	N/A
12/31/2016	4,050	545	N/A	553	N/A
9/30/2016	4,014	537	N/A	683	N/A
6/30/2016	3,986	535	N/A	652	N/A
3/31/2016	3,985	529	N/A	767	N/A
12/31/2015	3,935	532	N/A	743	N/A
9/30/2015	3,789	533	N/A	755	N/A
6/30/2015	3,645	507	N/A	836	N/A
3/31/2015	3,466	478	N/A	888	N/A
12/31/2014	3,355	470	N/A	979	N/A
9/30/2014	3,133	417	N/A	882	N/A
6/30/2014	2,972	388	N/A	712	N/A
3/31/2014	2,856	376	N/A	625	N/A
12/31/2013	2,742	346	N/A	592	N/A
9/30/2013	2,708	326	N/A	525	N/A
6/30/2013	2,685	306	N/A	573	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRFS's forecast earnings growth (28.8% per year) is above the savings rate (2.4%).

Earnings vs Market: GRFS's earnings (28.8% per year) are forecast to grow faster than the US market (14.1% per year).

High Growth Earnings: GRFS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GRFS's revenue (5.9% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: GRFS's revenue (5.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GRFS's Return on Equity is forecast to be low in 3 years time (11.5%).

Grifols Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Recent updates

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols: Q4 Was Positive, Still Too Many Question Marks

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols: I've Read The Short-Seller Report, And I Mostly Disagree

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Grifols inks 15-year deal with Canada for plasma-derived therapies

Grifols: Every Cloud Has A Silver Lining

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols: Long Only

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

Grifols shares rise after Andorra Development and Investment deal

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Grifols, S.A.(BME:GRF.P) dropped from S&P Global BMI Index

Grifols Begins Clinical Trial of A New Treatment That Would Provide Immediate Immunity Against Covid-19

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Grifols, S.A. Announces Board Appointments

Grifols, S.A. (BME:GRF) completed the acquisition of remaining 52.4% stake in Alkahest, Inc.

Grifols, S.A. Executes Binding Master Joint Venture Agreement with National Service Projects Organization

B. Braun Melsungen AG and Grifols Forms Strategic Alliance to Offer Integrated Solutions for Safe Automated Drug Preparation and Administration

Grifols Class B: Buy The Recovery In The U.S. Plasma Business

Grifols, S.A. (BME:GRF) acquired remaining 49% stake in Goetech LLC for $60.2 million.

Grifols S.A. goes ex-dividend tomorrow

Grifols' anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial in Patients with Covid-19

Grifols, S.A. (BME:GRF) agreed to acquire 53.4% stake in Green Cross Biotherapeutics Inc. from Green Cross North America Inc. for approximately KRW 190 billion.

Grifols, S.A. to Report Q3, 2020 Results on Nov 05, 2020

Grifols, S.A. (BME:GRF) completed the acquisition of Plasma Fractionation Facility in Montreal and Plasma Collection Centers in US from Green Cross Corporation (KOSE:A006280).

Grifols, S.A. (BME:GRF) agreed to acquire remaining 52.4% stake in Alkahest, Inc. for approximately $150 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies